Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EMBCNYSE:ENOVNASDAQ:LMATNASDAQ:NVCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMBCEmbecta$10.04-0.7%$11.49$9.76▼$21.48$586.77M1.13477,769 shs878,115 shsENOVEnovis$32.29-3.1%$33.22$29.13▼$49.83$1.84B1.71826,622 shs1.07 million shsLMATLeMaitre Vascular$81.37-2.1%$83.75$71.42▼$109.58$1.84B0.83167,818 shs103,908 shsNVCRNovoCure$18.20+4.8%$17.42$14.17▼$34.13$1.94B0.741.18 million shs1.43 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMBCEmbecta-0.69%+0.60%-19.68%-23.65%-21.50%ENOVEnovis-3.16%+2.20%-13.73%-12.75%-28.47%LMATLeMaitre Vascular-2.13%-2.43%-2.29%-0.66%+3.04%NVCRNovoCure+4.84%+10.64%+0.33%-6.62%-14.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMBCEmbecta4.2801 of 5 stars3.21.03.30.01.43.33.8ENOVEnovis2.7502 of 5 stars3.42.00.00.01.61.71.9LMATLeMaitre Vascular2.9545 of 5 stars2.22.03.30.03.12.51.3NVCRNovoCure4.0586 of 5 stars3.34.00.04.52.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMBCEmbecta 2.33Hold$19.3392.56% UpsideENOVEnovis 2.80Moderate Buy$58.0079.62% UpsideLMATLeMaitre Vascular 2.33Hold$97.8320.23% UpsideNVCRNovoCure 2.67Moderate Buy$32.8380.40% UpsideCurrent Analyst Ratings BreakdownLatest EMBC, NVCR, LMAT, and ENOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.005/23/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/14/2025ENOVEnovisCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.005/9/2025ENOVEnovisJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$62.00 ➝ $55.005/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $57.004/23/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.004/16/2025NVCRNovoCureWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $27.004/10/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$15.004/10/2025NVCRNovoCureJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $28.004/9/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMBCEmbecta$1.08B0.54$2.32 per share4.32($13.23) per share-0.76ENOVEnovis$2.15B0.86$4.71 per share6.86$62.66 per share0.52LMATLeMaitre Vascular$226.26M8.13$1.44 per share56.52$13.38 per share6.08NVCRNovoCure$621.71M3.26N/AN/A$3.39 per share5.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMBCEmbecta$78.30M$0.9010.043.270.785.25%-19.22%11.92%8/8/2025 (Estimated)ENOVEnovis-$33.26M-$13.95N/A10.12N/A-5.95%4.39%2.80%8/6/2025 (Estimated)LMATLeMaitre Vascular$30.10M$1.9844.4637.502.2219.40%13.15%11.47%7/30/2025 (Estimated)NVCRNovoCure-$207.04M-$1.51N/AN/AN/A-25.93%-41.48%-12.74%7/24/2025 (Estimated)Latest EMBC, NVCR, LMAT, and ENOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 million5/8/2025Q1 2025ENOVEnovis$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million5/1/2025Q1 2025LMATLeMaitre Vascular$0.50$0.48-$0.02$0.48$57.61 million$59.87 million4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMBCEmbecta$0.605.98%N/A66.67%N/AENOVEnovisN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.800.98%N/A40.40%14 YearsNVCRNovoCureN/AN/AN/AN/AN/ALatest EMBC, NVCR, LMAT, and ENOV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025EMBCEmbectaquarterly$0.154.51%5/28/20255/28/20256/13/20254/29/2025LMATLeMaitre Vascularquarterly$0.201%5/15/20255/15/20255/29/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMBCEmbectaN/A2.241.67ENOVEnovis0.402.271.12LMATLeMaitre VascularN/A7.745.52NVCRNovoCure0.271.491.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMBCEmbecta93.83%ENOVEnovis98.45%LMATLeMaitre Vascular84.64%NVCRNovoCure84.61%Insider OwnershipCompanyInsider OwnershipEMBCEmbecta0.42%ENOVEnovis2.70%LMATLeMaitre Vascular9.50%NVCRNovoCure5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMBCEmbecta1,90058.44 million57.89 millionOptionableENOVEnovis6,80057.12 million55.49 millionOptionableLMATLeMaitre Vascular49022.59 million20.06 millionOptionableNVCRNovoCure1,320111.49 million101.40 millionOptionableEMBC, NVCR, LMAT, and ENOV HeadlinesRecent News About These CompaniesNovoCure (NASDAQ:NVCR) Trading Up 6.5% - Here's WhyJune 10 at 2:14 PM | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Receives $32.83 Average Price Target from AnalystsJune 7, 2025 | americanbankingnews.comWedbush Estimates NovoCure's FY2026 Earnings (NASDAQ:NVCR)June 7, 2025 | americanbankingnews.comNVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 TrialJune 6, 2025 | zacks.comWhat is Wedbush's Estimate for NovoCure FY2026 Earnings?June 5, 2025 | marketbeat.comNovoCure (NASDAQ:NVCR) Sees Strong Trading Volume - Still a Buy?June 4, 2025 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Moderate Buy" by AnalystsJune 4, 2025 | marketbeat.comNovoCure (NASDAQ:NVCR) Shares Down 8.2% - Should You Sell?June 3, 2025 | marketbeat.comResults From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual MeetingJune 2, 2025 | businesswire.comNovocure data support pancreatic cancer approval, says Wells FargoJune 2, 2025 | msn.comNovocure study shows improved pancreatic cancer survivalJune 2, 2025 | massdevice.comNovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer TrialJune 2, 2025 | aol.comZai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual MeetingMay 31, 2025 | businesswire.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Stock Holdings in NovoCure Limited (NASDAQ:NVCR)May 29, 2025 | marketbeat.com1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall StreetMay 28, 2025 | msn.comNovocure Announces Upcoming Investor EventsMay 27, 2025 | finance.yahoo.comNovoCure Limited (NASDAQ:NVCR) Shares Sold by Two Sigma Investments LPMay 25, 2025 | marketbeat.comNovoCure Limited (NASDAQ:NVCR) Shares Sold by Voloridge Investment Management LLCMay 24, 2025 | marketbeat.comTwo Sigma Advisers LP Trims Stake in NovoCure Limited (NASDAQ:NVCR)May 24, 2025 | marketbeat.comNovoCure: Loading Up On Growth CatalystsMay 24, 2025 | seekingalpha.comBNP Paribas Financial Markets Sells 147,371 Shares of NovoCure Limited (NASDAQ:NVCR)May 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEMBC, NVCR, LMAT, and ENOV Company DescriptionsEmbecta NASDAQ:EMBC$10.04 -0.07 (-0.69%) As of 06/12/2025 04:00 PM EasternEmbecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Enovis NYSE:ENOV$32.29 -1.05 (-3.15%) As of 06/12/2025 03:58 PM EasternEnovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.LeMaitre Vascular NASDAQ:LMAT$81.37 -1.77 (-2.13%) As of 06/12/2025 04:00 PM EasternLeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.NovoCure NASDAQ:NVCR$18.20 +0.84 (+4.84%) As of 06/12/2025 04:00 PM EasternNovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
